Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage II-III Colorectal Cancer

* Stage II-III colorectal cancer patients scheduled to receive oxaliplatin 510 mg/m\^2 (cumulative dose) over 12 weeks as a component of adjuvant leucovorin calcium (calcium folinate), 5-fluorouracil and oxaliplatin (FOLFOX) treatment, in which patients are scheduled to receive oxaliplatin 85 mg/m\^2 every 2 weeks for 12 weeks (i.e., 6 cycles), or adjuvant capecitabine and oxaliplatin (CAPOX) treatment, in which patients are scheduled to receive oxaliplatin 135 mg/m\^2 every 3 weeks for 12 weeks (i.e., 4 cycles) * No prior neurotoxic chemotherapy * No pre-existing clinical or pre-clinical peripheral neuropathy from any cause. * No history of seizure disorder, * No history of narrow-angle glaucoma. * No symptoms of or history of schizophrenia, bipolar disease, suicidal thoughts and/or a major depression. * No serious eating disorder such as bulimia or anorexia. * No known diagnosis of ethanol (ETOH) addiction/dependence within the past 10 years. * Concomitant medications: * No concomitant use of other adjuvant pharmacologic interventions (e.g., gabapentin, pregabalin, venlafaxine) with known or hypothesized efficacy for peripheral neuropathy. Must be discontinued at least 7 days prior to start of protocol treatment * No anticipated or concurrent use of any antidepressant or serotonin-altering agent known to interact with duloxetine, due to concern regarding cumulative toxicity and potential drug interactions. * Use of a monoamine oxidase inhibitor (MAOI) or other antide…